CD147 | ||||||
Absent | Low | High | Total | P values | ||
Grade | 1 | 149 | 13 | 6 | 168 | 0.027 |
2 | 425 | 31 | 7 | 463 | ||
3 | 458 | 61 | 21 | 540 | ||
Total | 1032 | 105 | 34 | 1171 | ||
Apocrine phenotype | Absent | 942 | 91 | 31 | 1064 | 0.254 |
Present | 81 | 13 | 3 | 97 | ||
Total | 1023 | 104 | 34 | 1161 | ||
FF | Absent | 763 | 75 | 24 | 862 | 0.370 |
Present | 251 | 29 | 10 | 290 | ||
Total | 1014 | 104 | 34 | 1152 | ||
Necrosis | Absent | 815 | 89 | 29 | 933 | 0.141 |
Present | 206 | 15 | 5 | 226 | ||
Total | 1021 | 104 | 34 | 1159 | ||
LVI | Absent | 712 | 72 | 24 | 808 | 0.933 |
Present | 271 | 29 | 8 | 308 | ||
Total | 983 | 101 | 32 | 1116 | ||
EIC | Absent | 814 | 67 | 23 | 904 | <0.001 |
Present | 186 | 32 | 11 | 229 | ||
Total | 1000 | 99 | 34 | 1133 | ||
pT | 1 | 409 | 41 | 14 | 464 | 0.905 |
2 | 537 | 56 | 18 | 611 | ||
3 | 54 | 4 | 2 | 60 | ||
4 | 18 | 3 | 0 | 21 | ||
Total | 1018 | 104 | 34 | 1156 | ||
pN | 0 | 500 | 50 | 16 | 566 | 0.893 |
1 | 292 | 27 | 10 | 329 | ||
2 | 127 | 14 | 5 | 146 | ||
3 | 89 | 8 | 2 | 99 | ||
Total | 1008 | 99 | 33 | 1140 | ||
TIL | ≤20% | 632 | 62 | 17 | 711 | 0.162 |
>20% | 155 | 13 | 10 | 178 | ||
Total | 787 | 75 | 27 | 889 | ||
Subtype | LumA | 487 | 32 | 12 | 531 | <0.001 |
LumB | 303 | 38 | 10 | 351 | ||
HER2-OE | 106 | 6 | 2 | 114 | ||
BLBC | 52 | 19 | 8 | 79 | ||
5NP | 76 | 11 | 2 | 89 | ||
Total | 1024 | 106 | 34 | 1164 | ||
Histotype | IDC-NOS | 908 | 89 | 27 | 1024 | 0.041 |
Medullary CA | 37 | 9 | 4 | 50 | ||
Metaplastic CA | 9 | 2 | 0 | 11 | ||
ILC | 34 | 1 | 0 | 35 | ||
Others | 46 | 5 | 3 | 54 | ||
Total | 1034 | 106 | 34 | 1174 | ||
Age | Mean | 54.5 | 53.1 | 56.9 | 54.5 | 0.338 |
SD | 12.8 | 12.5 | 12.8 | 12.8 | ||
Range | 22–97 | 30–89 | 33–85 | |||
Tumour size | Mean | 2.69 | 2.69 | 2.72 | 2.69 | 0.914 |
SD | 1.48 | 1.32 | 1.53 | 1.47 | ||
Range | 0.1–13.0 | 1.0–7.0 | 1.0–8.0 |
BLBC, basal-like breast cancer; CA: carcinoma; EIC, extensive in situ component; FF, fibrotic focus; IDC-NOS, invasive ductal cancer-not otherwise specified; ILC, infiltrating lobular carcinoma; LVI, lymphovascular invasion; TIL, tumour-infiltrating lymphocyte.